VIRTUAL KOL EVENT
The Potential Role of Anti-OX40/OX40L Monoclonal Antibodies (mAbs) in the Treatment of Alopecia Areata (AA)
Wednesday, May 28th, 2025 | 11:00AM ET
Designed to be different:
Developing a potential best-in-class anti-OX40 treatment with features that matter to patients
ImageneBio is a clinical-stage biotechnology company developing therapeutics for patients who have immunological, autoimmune and inflammatory diseases. IMG-007 is our next-generation investigational anti-OX40 monoclonal antibody.
IMG-007
IMG-007 is an extended half-life anti-OX40 monoclonal antibody in clinical development that targets and inhibits OX40 receptor signaling without depleting T cells for potential enhanced efficacy, safety, and patient convenience.
News
November 12, 2025
ImageneBio Reports Third Quarter 2025 Financial Results and Provides IMG-007 Program Update Following Closing of Reverse Merger, Concurrent Financing, and Strengthening of Management Team
read more »August 01, 2025